* Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations
* Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies
